RT Journal Article
T1 Vericiguat in heart failure: From scientific evidence to clinical practice.
A1 González-Juanatey, J R
A1 Anguita-Sánchez, M
A1 Bayes-Genís, A
A1 Comín-Colet, J
A1 García-Quintana, A
A1 Recio-Mayoral, A
A1 Zamorano-Gómez, J L
A1 Cepeda-Rodrigo, J M
A1 Manzano, L
K1 GMPc
K1 Heart failure
K1 Insuficiencia cardíaca
K1 Nitric oxide
K1 Vericiguat
K1 cGMP
K1 Óxido nítrico
AB Despite currently available treatments, risk of death and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) remains high. The pathophysiology of HFrEF includes neurohormonal activation characterized by stimulation of deleterious pathways (i.e., sympathetic nervous and renin-angiotensin-aldosterone systems) and suppression of protective pathways such as nitric oxide-dependent pathways. Inhibition or stimulation of some, but not all, of these pathways is insufficient. In HFrEF, there is reduced nitric oxide, soluble guanylate cyclase, and cGMP activity, leading to deleterious effects in the myocardial, vascular, and renal systems. Vericiguat is able to stimulate the activity of this protective pathway. The VICTORIA study demonstrated that the addition of vericiguat to optimal medical treatment in patients with HFrEF and recent decompensation significantly reduced the incidence of the primary endpoint, a composite of cardiovascular death or HF hospitalization, with a number needed to treat of 24 patients and excellent tolerability.
YR 2022
FD 2022-04-23
LK http://hdl.handle.net/10668/22488
UL http://hdl.handle.net/10668/22488
LA en
DS RISalud
RD Apr 10, 2025